Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Perkin-Elmer

This article was originally published in The Gray Sheet

Executive Summary

Buyer is being sought for the firm's Analytical Instruments division following a review initiated in September 1998 to weigh strategic alternatives for the $600 mil.-a-year business ("The Gray Sheet" Sept. 14, 1998, p. 10). The AI unit markets a broad range of analytical chemistry systems used in clinical and biological analysis and in pharmaceutical development to identify and measure changes in properties of solids, liquids and gases. Perkin-Elmer would retain its $900 mil.-a-year PE Biosystems division and the newly formed Celera Genomics gene-based information joint venture with The Institute for Genomics Research

You may also be interested in...



UK Government Backs Vitamin D COVID Benefits With Supplement Handout

By handing out free supplements to the clinically vulnerable, the UK government is effectively endorsing the use of vitamin D to reduce the risk and/or severity of COVID-19, although it says more research is needed.

UK's Redx Rises On Stock Sale

A few months after bringing AstraZeneca onboard as a partner, the turnaround at the Alderley Park-based firm is moving ahead, buoyed by a fresh financing.

Calm Before The Storm – But Some Medtechs Already Reflect The Ravages Of COVID-19

2019 saw fewer revenue-boosting major acquisitions by top-tier medtechs. Companies that reported after the calendar year-end were the first to see the consequences of the pandemic on their annual figures.

UsernamePublicRestriction

Register

OM004514

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel